- Country: TAIWAN
- Official Title: 執行長兼醫療長/顧問醫師/特約醫師/兼任副教授
- Department: 樂迦再生科技股份有限公司/馬偕紀念醫院/臺中榮民總醫院/北醫細胞治療與再生醫學系
Speech Title
CAR-T for T-Cell Lymphoma Perspectives
CAR-T cell therapy has revolutionized the treatment of B-cell malignancies, but its application in T-cell lymphoma is still emerging. T-cell lymphoma presents unique challenges due to its heterogeneity, limited specific targets, and potential for “self-tolerance” issues. Current research focuses on identifying suitable targets, such as CD5 and CD4, while addressing safety concerns like cytokine release syndrome (CRS) and neurotoxicity. Early clinical trials show promise, but further investigation is needed to refine treatment protocols and improve long-term outcomes. Continued advancements in CAR-T technology and clinical insights are crucial for enhancing its efficacy and safety in T-cell lymphoma.